AR and neoplasm: Regarding the PIK3CA mutation rate (15.1%), our results are in accordance with the literature.11 Lehmann et al showed that PIK3CA mutations were significantly enriched among LAR TNBCs (46.2%) compared to all other TNBC subtypes (4.5%), with a predominance of exon 20 mutations that encode the catalytic domain of PI3K.5 We observed similar results with 27.7% of PIK3CA mutations in AR + TNBC (16.1% on exon 20) compared to 3.3% in AR- tumours (all on exon 9).